Table 1 Overall expression of class I HDAC isoforms in prostate carcinoma as well as distribution of class I HDAC isoform expression in the study population stratified for selected tumour parameters

From: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

 

Total

HDAC1 low

HDAC1 high

P -value

HDAC2 low

HDAC2 high

P -value

HDAC3 low

HDAC3 high

P -value

All cases

192 (100%)

58 (30.2%)

134 (69.8%)

 

50 (26%)

142 (74%)

 

10 (5.2%)

182 (94.8%)

 

PSA ⩽10 ng ml−1

75 (48.1%)

23 (30.7%)

52 (69.3%)

0.610+

23 (30.7%)

52 (69.3%)

0.474+

4 (5.3%)

71 (94.7%)

1.000+

PSA >10 ng ml−1

81 (51.9%)

29 (35.8%)

52 (64.2%)

 

20 (24.7%)

61 (75.3%)

 

5 (6.2%)

76 (93.8%)

 

Age ⩽65

134 (69.8%)

43 (32.1%)

91 (67.9%)

0.494+

29 (21.6%)

105 (78.4%)

0.048+

8 (6%)

126 (94%)

0.726+

Age >65

58 (30.2%)

15 (25.9%)

43 (74.1%)

 

21 (36.2%)

37 (63.8%)

 

2 (3.4%)

56 (96.6%)

 

pT2

97 (50.5%)

32 (33%)

65 (67%)

0.580*

28 (28.9%)

69 (71.1%)

0.398*

5 (5.2%)

92 (94.8%)

0.925*

pT3

91 (47.4%)

24 (26.4%)

67 (73.6%)

 

21 (23.1%)

70 (76.9%)

 

5 (5.5%)

86 (94.5%)

 

pT4

4 (2.1%)

2 (50%)

2 (50%)

 

1 (25%)

3 (75%)

 

0 (0%)

4 (100%)

 

Gleason sum 2–6

70 (36.5%)

31 (44.3%)

39 (55.7%)

0.006*

24 (34.3%)

46 (65.7%)

0.047*

5 (7.1%)

65 (92.9%)

0.584*

Gleason sum 7

64 (33.3%)

14 (21.9%)

50 (78.1%)

 

15 (23.4%)

49 (76.6%)

 

2 (3.1%)

62 (96.9%)

 

Gleason sum 8–10

58 (30.2%)

13 (22.4%)

45 (77.6%)

 

11 (19%)

47 (81%)

 

3 (5.2%)

55 (94.8%)

 

R0

100 (52.1%)

29 (29%)

71 (71%)

0.754+

30 (30%)

70 (70%)

0.249+

5 (5%)

95 (95%)

1.000+

R1

92 (47.9%)

29 (31.5%)

63 (68.5%)

 

20 (21.7%)

72 (78.3%)

 

5 (5.4%)

87 (94.6%)

 

HDAC1 low

58 (30.2%)

—

—

—

23 (39.7%)

35 (60.3%)

0.007+

10 (17.2%)

48 (82.8%)

<0.001+

HDAC1 high

134 (69.8%)

—

—

 

27 (20.1%)

107 (79.9%)

 

0 (0%)

134 (100%)

 

HDAC2 low

50 (26%)

23 (46%)

27 (54%)

0.007+

—

—

—

7 (14%)

43 (86%)

0.004+

HDAC2 high

142 (74%)

35 (24.6%)

107 (75.4%)

 

—

—

 

3 (2.1%)

139 (97.9%)

 

HDAC3 low

10 (5.2%)

10 (100%)

0 (0%)

<0.001+

7 (70%)

3 (30%)

0.004+

—

—

—

HDAC3 high

182 (94.8%)

48 (26.4%)

134 (73.6%)

 

43 (23.6%)

139 (76.4%)

 

—

—

 

Ki-67 index mean

8.60

6.88

9.30

0.032#

6.44

9.30

0.002#

4.00

8.83

<0.001#

Ki-67 index s.d.

6.62

0.82

0.63

 

0.61

0.64

 

0.63

0.53

 

DFS probability median

0.70

0.80

0.60

0.203$

0.83

0.60

0.036$

0.60

0.70

0.946$

DFS probability quart.

0.3–0.9

0.30–0.91

0.30–0.86

 

0.40–0.93

0.30–0.85

 

0.20–0.90

0.30–0.90

 
  1. DFS=disease-free survival; HDAC=histone deacetylase.
  2. In the first row overall distribution of the respective tumour parameters in the study population is listed.
  3. +Fisher's exact test, *χ2-test for trends, #unpaired t-test $, Mann–Whitney U-test.
Back to article page